Teva Concludes Enrollment for Schizophrenia Drug Trial

Teva Completes Enrollment for Schizophrenia Drug Trial: Phase 3 Results Anticipated in 2024

Teva Pharmaceutical Industries Ltd. has successfully completed patient enrollment for its Phase 3 trial of mdc-TJK, an innovative potential treatment for schizophrenia. The trial has enrolled 640 participants across the European Union and the United States, with results expected to be available in the latter half of 2024.